Edwards, John
John Edwards brings over 30 years of experience in discovery, development, and global commercialization of biopharmaceuticals. He was involved in the development or commercialization of ten FDA-approved biologics and has had successful exits at eight of the ten biotech companies he helped to build, including Tilos Therapeutics, Siamab Therapeutics, Exonics Therapeutics, Adnexus Therapeutics, F-star Therapeutics,

John Edwards
Executive Chair and Interim CEO

John Edwards
Executive Chair and Interim CEO
Greenberg, Steven A.
Steven A Greenberg, M.D., M.S. is a founder of Abcuro and is the Chair of the Medical Advisory Board. Steve is a clinical neurologist at Brigham and Women’s Hospital, and Professor of Neurology at Harvard Medical School. His clinical and laboratory research focus involves translational medicine, inventing diagnostics including blood tests for dermatomyositis and inclusion

Steven A. Greenberg, MD
Chief Scientific Advisor and
Chair, Medical Advisory Board

Steven A. Greenberg, MD
Chief Scientific Advisor and
Chair, Medical Advisory Board
Wilkins, Jeffrey
Jeffrey Wilkins is the Chief Medical Officer of Abcuro. He is a highly experienced clinician, having advanced clinical programs from IND to regulatory approval. Jeff has deep expertise in the areas of immunology, rare diseases, and immuno-oncology. He has served in senior clinical leadership positions, including as Chief Medical Officer for over 20 years. Among

H. Jeffrey Wilkins, MD
Chief Medical Officer

H. Jeffrey Wilkins, MD
Chief Medical Officer
Jeffrey Wilkins is the Chief Medical Officer of Abcuro. He is a highly experienced clinician, having advanced clinical programs from IND to regulatory approval. Jeff has deep expertise in the areas of immunology, rare diseases, and immuno-oncology. He has served in senior clinical leadership positions, including as Chief Medical Officer for over 20 years. Among others, Jeff led clinical development programs at Avalo Therapeutics, Lycera, Ceptaris Therapeutics, Cephalon, and Ception Therapeutics. He entered the pharmaceutical industry with GlaxoSmithKline, where he rose to become Vice President of Discovery Medicine for GSK’s Center of Excellence in External Drug Discovery. Jeff received his M.D. from Temple University School of Medicine and his B.S. from Bucknell University.
Courtemanche, Kate
Kate Courtemanche is the Chief Development Officer of Abcuro. She is an industry leader with extensive drug development expertise in recombinant proteins and vaccines, as well as lentiviral and adeno-associated virus vectors, and oligonucleotides. Kate’s experience spans many therapeutic areas, including oncology, neurology, ophthalmology, infectious disease, autoimmune disease, stem cell therapy, gene therapy, and coagulation

Kate Courtemanche
Chief Development Officer

Kate Courtemanche
Chief Development Officer
Subramanyam, Janaki
Janaki (Jana) Subramanyam is Vice President, Head of Regulatory Affairs at Abcuro. Jana is an experienced regulatory affairs professional having worked on small molecule and biologic development programs across rheumatology, nephrology, neurology, and psychiatry for more than twenty years. Her regulatory drug development expertise spans clinical, nonclinical, manufacturing, quality, post marketing advertising, and promotional activities.

Janaki M. Subramanyam
VP, Head of Regulatory Affairs

Janaki M. Subramanyam
VP, Head of Regulatory Affairs